Danaher Corp /de/ (DHR) · Oct 13, 2026 · Exec change
Board expanded — 13 directors after two appointments
Danaher’s board expands with a former CFO and biotech scientist, while longtime director Alan Spoon plans to retire at the 2027 annual meeting.
Danaher is a science-and-technology company organized around biotechnology, life sciences, and diagnostics, while pushing deeper into tools that accelerate drug discovery and laboratory research.
The board is adding targeted expertise, not changing operating leadership. Danaher increased its board to 13 members and appointed former CFO Daniel Comas and biotech executive Robert Hershberg, with Hershberg joining the Science and Technology Committee. Comas brings deep institutional knowledge of Danaher’s finance, treasury, risk management, and acquisition history; Hershberg adds external drug-development and biotechnology experience. That combination fits the company’s current science-heavy portfolio, but it does not itself alter strategy, capital allocation, or execution.
The Comas appointment formalizes a transition that was already underway. His consulting agreement ended September 30, 2026, when he joined the board, after he earned $525,000 in 2025 and $393,750 in 2026 for strategic advice. 〔0〕 This makes the change more governance-oriented than operational: Danaher retains his institutional perspective without keeping him in an executive or consulting role.
The offset is a planned board departure, not a governance dispute. Alan Spoon will retire at the 2027 annual meeting and will not stand for re-election; the filing explicitly says the decision was not due to disagreement with Danaher. 〔1〕
Bottom line: This is a measured board refresh that strengthens finance and biotechnology coverage while preserving continuity. It matters for oversight, but it does not materially change Danaher’s business trajectory today; the market had no clean earnings-style benchmark against which to score it.
2027 annual meeting shareholder vote on director nominees
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!